NeoTherapeutics' AIT-082 In Spinal Cord Injury

30 October 1997

- After seven days of treatment with NeoTherapeutics' flagship compound,AIT-082, rats with spinal cord injuries were found to have increased levels of cilliary neurotrophic factor and brain-derived neurotrophic factor, which have been shown to play an important part in the regeneration of spinal cord motor neurons in cell culture studies. The company says that it may begin clinical studies in this area after animal studies are completed. AIT-082 is currently in clinical trials for the treatment of Alzheimer's disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight